RESUMEN
In the last years, actigraphy has been used more often for clinical research and research evaluation of sleep disorders. Compared to polysomnography, actigraphy is cheap and less time-consuming. Actigraphy provides more objective information about sleep than sleep logs. Although the algorithms to score sleep and wake based on motions measured by actigraphy are still being improved, we believe that the role of actigraphy in the clinical evaluation of sleep in insomnia is limited. Instead of using actigraphy to distinguish a wakeful state from sleep in insomnia, we might better use the activity plots which the actigraph provides to get more insight into the physiological hyperarousal or restfulness of insomnia patients.
Asunto(s)
Monitoreo Fisiológico/instrumentación , Pautas de la Práctica en Medicina , Trastornos del Inicio y del Mantenimiento del Sueño/diagnóstico , Adulto , Femenino , Humanos , Masculino , Factores de Tiempo , Vigilia/fisiologíaRESUMEN
There is growing public concern about the use of gamma-hydroxybutyrate (GHB) as a party drug. This justified concern about misuse, however, should not lead to prohibition of the drug as it is efficacious in narcolepsy.
Asunto(s)
Estimulantes del Sistema Nervioso Central/uso terapéutico , Control de Medicamentos y Narcóticos/legislación & jurisprudencia , Narcolepsia/tratamiento farmacológico , Oxibato de Sodio/uso terapéutico , Trastornos Relacionados con Sustancias/prevención & control , Estimulantes del Sistema Nervioso Central/administración & dosificación , Humanos , Drogas Ilícitas/legislación & jurisprudencia , Países Bajos , Oxibato de Sodio/administración & dosificaciónRESUMEN
Poor sleep is a common complaint, accounting for 4-5% of all general practitioner consultations. Disorders of initiating sleep are overrated by patients compared with disorders of maintaining sleep, despite the greater effect of the latter on daytime performance. There is frequently a discrepancy between subjective observations and objective measurements of sleep. General practitioners should pay attention to sleep disorders lasting more than three weeks and should bear in mind that poor sleep is a symptom, the underlying cause of which needs to be determined. Good coordination of endogenous biorhythms and external life and working circumstances can positively influence sleeping patterns. Sleep onset latency determines the amount of deep sleep and, thus, the duration and stability of core sleep. General practitioners usually prescribe a single type of benzodiazepine drug with a half-life of 5-10 h for sleep disorders. Such drugs cause the patient to fall asleep quickly, to have a considerable period of uninterrupted sleep with little waking and to wake in the morning with a subjective feeling of having slept well. A number of less desirable changes can occur, however, that may produce, for example, anxiety dreams, increased snoring and sleep apnoea periods at night, and weakness of muscles during the day. The third generation of hypnotic agents produce less undesirable changes than the second generation. Zolpidem (an imidazoypridine), one such agent, seems to provide an effective treatment for insomnia without inducing undesirable side-effects.
Asunto(s)
Ritmo Circadiano , Trastornos del Sueño-Vigilia/terapia , Sueño REM , Adulto , Medicina Familiar y Comunitaria , Humanos , Polisomnografía , Trastornos del Inicio y del Mantenimiento del Sueño/etiología , Trastornos del Inicio y del Mantenimiento del Sueño/terapia , Trastornos del Sueño-Vigilia/diagnóstico , Factores de TiempoRESUMEN
In order to test the assumption that the sleep stability increases as the number of shifts and awakenings decreases, all-night sleep recordings (registered at home) were reanalyzed. The registrations belong to 10 young good sleepers, 10 adult good sleepers, 10 insomnia patients without treatment, 10 treated with a benzodiazepine and 10 treated with a nonbenzodiazepine hypnotic, 10 patients with proven narcolepsy, and 10 with obstructive sleep apnea syndrome (OSAS). For each of the categories NREM-1-2, NREM 3-4, and REM sleep, indices were defined as the number of shifts and awakenings that occurred per hour. Our results show that the indices of awakenings for the good as well for the bad sleepers were similar, whereas the indices of awakenings were very group dependent. We interpreted these results as showing that awakenings are valuable indicators for studying the quality of sleep, whereas shifts are not.
Asunto(s)
Hipnóticos y Sedantes/farmacología , Movimiento/fisiología , Sueño/fisiología , Adolescente , Adulto , Anciano , Nivel de Alerta/efectos de los fármacos , Humanos , Hipnóticos y Sedantes/uso terapéutico , Persona de Mediana Edad , Narcolepsia/tratamiento farmacológico , Narcolepsia/fisiopatología , Sueño/efectos de los fármacos , Síndromes de la Apnea del Sueño/tratamiento farmacológico , Síndromes de la Apnea del Sueño/fisiopatología , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Sueño REM/efectos de los fármacosRESUMEN
We treated 24 patients with narcolepsy for 4 weeks with gammahydroxybutyrate (GHB), 60 mg/kg/night, in a randomized double-blind placebo-controlled cross-over trial. Both clinical and polysomnographic criteria were used to assess the results. Compared to placebo, GHB reduced the daily number of hypnagogic hallucinations (from 0.87 to 0.28; p = 0.008), daytime sleep attacks (from 2.27 to 1.40; p = 0.001) and the severity of subjective daytime sleepiness (from 1.57 to 1.24 on a 0-4 scale; p = 0.028). The number of daily cataplexy attacks was reduced from 1.26 at baseline to 0.56 after 4 weeks of GHB intake. This reduction, however, was not statistically significantly different from the difference between baseline and placebo. GHB stabilized nocturnal rapid eye movement (REM) sleep, i.e. it reduced the percentage of wakefulness during REM sleep (p = 0.007) and the number of awakenings out of REM sleep (p = 0.016), and tended to increase slow wave sleep (p = 0.053). Adverse events were few and mild. We conclude that GHB is an effective and well-tolerated treatment for narcolepsy.
Asunto(s)
Hidroxibutiratos/uso terapéutico , Narcolepsia/tratamiento farmacológico , Adolescente , Adulto , Anciano , Encéfalo/efectos de los fármacos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Narcolepsia/diagnóstico , Placebos , Polisomnografía , Sueño/efectos de los fármacos , Sueño REM/efectos de los fármacos , Vigilia/efectos de los fármacosAsunto(s)
Trastornos del Sueño-Vigilia/diagnóstico , Adulto , Codeína/uso terapéutico , Femenino , Humanos , Hipnóticos y Sedantes/uso terapéutico , Masculino , Persona de Mediana Edad , Psicoterapia , Síndrome de las Piernas Inquietas/diagnóstico , Síndrome de las Piernas Inquietas/tratamiento farmacológico , Trastornos del Sueño-Vigilia/psicología , Trastornos del Sueño-Vigilia/terapiaRESUMEN
We prospectively studied the reliability and accuracy of the electroencephalogram as a predictor of the risk of recurrence within 2 years in 157 patients with untreated idiopathic first seizures. In all patients, a standard electroencephalogram and, if necessary, an electroencephalogram after partial sleep deprivation were obtained. All electroencephalograms were scored by one observer according to a fixed protocol. The finding of epileptic discharges was associated with a risk of recurrence of 83% (95% confidence interval, 69% to 97%) vs 41% (95% confidence interval, 29% to 53%) in patients with nonepileptic abnormalities and 12% (95% confidence interval, 3% to 21%) in patients in whom both electroencephalograms were normal. The sensitivity proved to be 48%. Interobserver agreement among four neurologists, who independently read 50 electroencephalograms, was found to be moderate. Predictive value for each observer, however, was good. We conclude that electroencephalogram findings may play a role in the decision to initiate or delay treatment after an idiopathic first seizure.
Asunto(s)
Electroencefalografía , Convulsiones/diagnóstico , Potenciales de Acción , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Encéfalo/fisiopatología , Electroencefalografía/normas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Valor Predictivo de las Pruebas , Estudios Prospectivos , Recurrencia , Convulsiones/epidemiología , Convulsiones/fisiopatología , Privación de SueñoRESUMEN
Eighteen non-pregnant woman complaining about insomnia were polysomnographically investigated for 3 nights with weekly intervals. They received placebo, 2 mg flunitrazepam or 10 mg zolpidem according to a cross-over double blind design. The patients were selected by general practitioners on the basis of subjective complaints. Zolpidem is a recently introduced short-acting imidazopyridine hypnotic, binding to a subunit of the benzodiazepine 1 receptor. Flunitrazepam is a well-known hypnotic, binding to both the benzodiazepine 1 and 2 receptor subtypes. Objective recording did not substantiate the subjective complaint of insomnia. Sleep patterns during placebo differed only little from that expected from age matched healthy persons. Both flunitrazepam and zolpidem significantly shortened sleep onset (5 min of continuous sleep beginning with NREM 1 sleep). The sleep composition following flunitrazepam was characterized by an increase in NREM 2, a prolongation of the time of REM sleep, a reduction of REM sleep and an increase in NREM 3-4 sleep during the first 2 h of sleep. The sleep composition following zolpidem resembled more than seen in persons without sleep complaints. However, as compared to placebo, there was a decrease of the time spent awake during sleep and an increase in NREM 3-4 during the first 2 of sleep.
Asunto(s)
Flunitrazepam/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Piridinas/uso terapéutico , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Sueño/efectos de los fármacos , Adulto , Método Doble Ciego , Femenino , Humanos , Trastornos del Inicio y del Mantenimiento del Sueño/psicología , Sueño REM/efectos de los fármacos , ZolpidemRESUMEN
In the present study children suffering from primary generalized absence epilepsy were asked to estimate time under EEG monitoring. They were asked to press a button when they thought that a fixed period of time had elapsed. Only the first response after the passage of the interval was reinforced. The dependent variable was the duration of the interval between the start of the trial and the first response, the post-reinforcement time. This parameter was used as an index for the accuracy of time estimation. The performance of the subjects in trials with and without spike wave discharges was compared. Short spike wave discharges (less than 3 s) prolonged the duration of the post-reinforcement pause while longer ones reduced its duration. The prolongation was longer than could be anticipated from the duration of the spike wave discharge. It was also found that the time between the end of an EEG paroxysm and the first response was significantly shorter in trials with long spike wave discharges than in trials with short spike wave discharges. There were no differences between subjects with and without spike wave discharges. It was concluded that this type of time estimation task is sensitive in detecting cognitive disturbances induced by both short and long spike wave discharges. Moreover, it seems that after long spike wave discharges patients behave differently and are perhaps more severely disturbed.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Epilepsia Tipo Ausencia/psicología , Percepción del Tiempo , Adolescente , Niño , Condicionamiento Operante , Electroencefalografía , Humanos , Esquema de RefuerzoRESUMEN
In a double-blind placebo-controlled trial, ritanserin (a 5-HT2 receptor blocker) 5 mg/day or placebo was added to the usual medication in 28 patients with narcolepsy during 4 wk. The effect was assessed by means of polysomnography, daily and weekly subjective evaluations, and Multiple sleep latency tests (MSLT). During the night ritanserin increased the amount of nonrapid eye movement slow wave sleep and reduced wakefulness after sleep onset. It improved the feeling of being refreshed in the morning after awakening and reduced subjective daytime sleepiness. The drug did not significantly influence sleep latency in the MSLT.
Asunto(s)
Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Narcolepsia/tratamiento farmacológico , Piperidinas/uso terapéutico , Adolescente , Adulto , Animales , Ritmo Circadiano/efectos de los fármacos , Método Doble Ciego , Humanos , Persona de Mediana Edad , Placebos , Ritanserina , Sueño/efectos de los fármacosAsunto(s)
Anticonvulsivantes/uso terapéutico , Encéfalo/efectos de los fármacos , Electroencefalografía/efectos de los fármacos , Epilepsia/tratamiento farmacológico , Fases del Sueño/efectos de los fármacos , Adolescente , Adulto , Ansiolíticos/efectos adversos , Ansiolíticos/uso terapéutico , Anticonvulsivantes/efectos adversos , Benzodiazepinas , Encéfalo/fisiopatología , Carbamazepina/efectos adversos , Carbamazepina/uso terapéutico , Niño , Preescolar , Quimioterapia Combinada , Epilepsia/fisiopatología , Etosuximida/efectos adversos , Etosuximida/uso terapéutico , Femenino , Humanos , Cuidados a Largo Plazo , Masculino , Fenobarbital/efectos adversos , Fenobarbital/uso terapéutico , Fenitoína/efectos adversos , Fenitoína/uso terapéutico , Estudios Retrospectivos , Privación de Sueño/fisiología , Fases del Sueño/fisiología , Ácido Valproico/efectos adversos , Ácido Valproico/uso terapéuticoRESUMEN
A vigilance state is characterized by a particular activity state of the motorIautonomic and psychiclcognitive functional systems. S-W screening is possible through poly graphic monitoring of physiological variables and signals. Quantification of these signals introduces a set of parameters allowing the characterisation of the sleep (dys)function. There is no consensus regarding the choice or definition of these parameters. A particular cluster is presented and their informative value with respect to clinical practice and research is discussed.
RESUMEN
In this study effects of temazepam on the EEGs of 10 healthy volunteers were detected using a standardized EEG registration procedure applied in a controlled environment. The EEGs were recorded both before and after administration of 20 mg temazepam as well as before and after placebo. A mean power spectrum was computed for each EEG from the 'eyes closed' condition, and the Student t test was used to detect differences in the spectra of the pre- and posttreatment EEGs in both placebo and drug conditions. For all 10 subjects the drug condition was easily distinguishable from the placebo condition based on the results of the t test.
Asunto(s)
Ansiolíticos/farmacología , Nivel de Alerta/efectos de los fármacos , Electroencefalografía/efectos de los fármacos , Procesamiento de Señales Asistido por Computador , Temazepam/farmacología , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Potenciales Evocados/efectos de los fármacos , Femenino , Humanos , MasculinoRESUMEN
In order to improve the diagnosis of epilepsy, a routine EEG recording can be supplemented with a long-lasting sleep recording or with an ambulatory EEG recording. In this paper we compare the all-night polygraphic sleep recording with the 3- to 5-hour recording after 1 night total sleep deprivation, and we discuss the outcome with each. In the first part we have analyzed the relationship between the clinical form of epilepsy and the kind and depth of sleep and we have tried to determine the optimal registration time (in hours) to obtain a maximum diagnostic gain. In the second part we have evaluated the changes in the sleep composition induced by the occurrence of epileptic EEG phenomena and by the intake of antiepileptic drugs. In the third part we have analyzed the changes in the morphological aspects of the epileptic EEG phenomena which can occur under influence of light (NREM 1-2) and deep (NREM 3-4) slow-wave sleep and REM sleep. A sufficient knowledge of these changes is very important to avoid misinterpretations.
Asunto(s)
Epilepsia/fisiopatología , Sueño/fisiología , Electroencefalografía , Epilepsia/diagnóstico , Humanos , Inteligencia , Monitoreo Fisiológico , Privación de Sueño , Fases del SueñoRESUMEN
In this paper we describe one hardware and two software automated sleep spindle detection methods, used in our laboratory. With each of the three methods at least 500 polygraphic sleep recordings were analyzed and the results compared with the outcome of the visual analysis. In this way we were able to evaluate the advantages and the disadvantages of each of the three methods and also to discuss the practical application of this method for clinical and scientific purposes, as for example a better quantification of the variation in sleep spindle density under influence of the intake of benzodiazepine derivatives.
Asunto(s)
Electroencefalografía/métodos , Procesamiento Automatizado de Datos/métodos , Sueño/fisiología , Humanos , Microcomputadores , Programas InformáticosRESUMEN
The transient visual-evoked potentials (VEP), recorded in patients suffering from generalized epilepsy, can be characterized by a duplication of the negative peak with a latency of 70-100 ms, a strong increase in amplitude of the negative peak between 80 and 130 ms and the development of a high amplitude slow negative wave following the primary complex. In this study we have investigated to which degree these changes are influenced by the intravenous administration of clonazepam and sodium valproate. Therefore, VEPs were registered in 30 patients, suffering from generalized epilepsy, just before and immediately after the intravenous injection of 0.4-0.8 mg clonazepam and further at 15, 30 and 16 min thereafter. The same procedure was applied on 10 patients treated with an intravenous injection of 400 mg sodium valproate. In both groups we found more or less a reduction in number and degree of the mentioned VEP changes. The improvement was associated with a strong decrease in amplitude of the VEP components in the group treated with clonazepam but was not seen in the sodium valproate group.
Asunto(s)
Benzodiazepinonas/uso terapéutico , Clonazepam/uso terapéutico , Epilepsia/tratamiento farmacológico , Ácido Valproico/uso terapéutico , Adolescente , Adulto , Encéfalo/fisiopatología , Niño , Epilepsia/fisiopatología , Potenciales Evocados Visuales , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Sleep-wakefulness patterns recorded following 1 night total sleep deprivation were studied in 15 normal subjects and in 252 epileptic patients. The patients were taking various types and combinations of antiepileptic medication. Sleep deprivation caused a reduction in sleep latency and an increase in NREM stage 3 + 4 sleep. This effect persisted in patients treated with valproate sodium and/or carbamazepine. In patients treated with diphenylhydantoin light NREM 1 + 2 sleep increased. In those treated with antiepileptics + chlorazepate, both an increase in NREM 1 + 2 and NREM 3 + 4 sleep was seen. The former probably reflects a benzodiazepine effect, the latter is due to a sleep deprivation effect. In patients treated with antiepileptics + clonazepam, a benzodiazepine effect predominated.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Sueño/fisiología , Adolescente , Adulto , Carbamazepina/uso terapéutico , Niño , Quimioterapia Combinada , Epilepsia/fisiopatología , Humanos , Persona de Mediana Edad , Fenitoína/uso terapéutico , Privación de Sueño , Ácido Valproico/uso terapéuticoRESUMEN
A case of an 11-year-old boy with an autosomal dominant form of paroxysmal kinesigenic choreoathetosis is presented. Routine EEG, sleep EEG recording, and registration of visual evoked potentials and somatosensory evoked potentials were normal. EEG with videomonitoring and registration of event-related potentials, however, showed abnormalities, which are discussed in detail. Our data provide further arguments in support of the hypothesis that paroxysmal kinesigenic choreoathetosis is the expression of a dysbalance in the cortico-striopallidal-thalamic loop, and has an extrapyramidal genesis.